ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia

por Jean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, Nicolas Duployez, Eunhee Kim, Stanley Chun-Wei Lee, Benjamin H. Durham, Young Rock Chung, Hana Cho, Xiao Jing Zhang, Akihide Yoshimi, Andrei Krivtsov, Richard Koche, Eric Solary, Amit Sinha, Claude Preudhomme, Omar Abdel-Wahab
Publicado 2017

Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis

por Shuhei Asada, Susumu Goyama, Daichi Inoue, Shiori Shikata, Reina Takeda, Tsuyoshi Fukushima, Taishi Yonezawa, Takeshi Fujino, Yasutaka Hayashi, Kimihito Cojin Kawabata, Tomofusa Fukuyama, Yosuke Tanaka, Akihiko Yokoyama, Satoshi Yamazaki, Hiroko Kozuka-Hata, Masaaki Oyama, Shinya Kojima, Masahito Kawazu, Hiroyuki Mano, Toshio Kitamura
Publicado 2018

Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway

por Takeshi Fujino, Susumu Goyama, Yuki Sugiura, Daichi Inoue, Shuhei Asada, Satoshi Yamasaki, Akiko Matsumoto, Kiyoshi Yamaguchi, Yumiko Isobe, Akiho Tsuchiya, Shiori Shikata, Naru Sato, Hironobu Morinaga, Tomofusa Fukuyama, Yosuke Tanaka, Tsuyoshi Fukushima, Reina Takeda, Keita Yamamoto, Hiroaki Honda, Emi K. Nishimura, Yoichi Furukawa, Tatsuhiro Shibata, Omar Abdel-Wahab, Makoto Suematsu, Toshio Kitamura
Publicado 2021